Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: Role of ruxolitinib in improving survival outcomes

Primary myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid proliferation, splenomegaly, bone marrow fibrosis, and heterogenous symptom burden [1-3]. Non-transplant treatment options have traditionally included cytoreductive therapies (hydroxyurea, busulfan, interferon- α), immunomodulatory drugs, androgens, splenic irradiation and splenectomy – though these are primarily palliative [4]. In the last decade, major advances in the understanding of the molecular basis of MF have been achieved, importantly the pivotal role of the JAK-STAT pathway.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research